Table 1.
Comparison between WHO-prequalified cholera vaccines and Vaxchora™.
| Vaccine | Dukoral® | ShancholTM | Euvichol® | VaxchoraTM |
|---|---|---|---|---|
| Manufacturer | Valneva, France | Shantha Biotechnics, (Hyderabad, India) Sanofi Company | Eubiologics, Seoul, Republic of Korea | PaxVax Inc., US |
| Developer | SBL Vaccin (Solna, Sweden) | IVI, Shantha | IVI, Eubiologics | PaxVax Inc. (US) Univ. of Maryland and Kentucky |
| Type | Monovalent, killed whole-cell vaccine O1 serogroup and recombinant cholera toxin B subunit | Bivalent, killed whole-cell (O1 and O139 serogroups) | Bivalent, killed whole-cell (O1 and O139 serogroups) | Monovalent, live, attenuated serogroup O1 classical Inaba strain 569B |
| Age range for vaccination | ≥ 2 years | 1 year and older | 1 year and older | 18–64 yrs |
| Regimen | 2 doses given 7 to 14 days apart (3 doses for children 2 to 5 yrs old) | Two doses 14 days apart | Two doses 14 days apart | Single dose |
| Booster | Every 2 years for individual ≥6 yrs (every 6 mo for children 2 to 5 yrs) | No recommendation from manufacturer | No recommendation from manufacturer | No recommendation from manufacturer |
| Route | Oral | Oral | Oral | Oral |
| Buffer | Sodium bicarbonate buffer | No buffer required | No buffer required | Blend of sodium bicarbonate, sodium carbonate, ascorbic acid, and dried lactose |
| Duration of protection | 2 years (6 months in children 2 to 5 yrs) | At least 3 years Up to 5 yrs | Not available | Not available |
| Storage | +2°C to +8°C | +2°C to +8°C | +2°C to +8°C | −25°C to −15°C |
| Shelf Life | 36 months | 24 months | 24 months | 24 months |
| Licensure | 60 countries | 28 countries | Zambia, Nepal and Pakistan | Approved US FDA, June 2016 |
| WHO prequalification | 25 Oct 2001 | 29 Sep 2011 | 23 Dec 2015 | No |